U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   FORM 10-QSB
 (Mark One)

     [X]  Quarterly  report  pursuant  to section 13 or 15(d) of the  Securities
          Exchange Act of 1934 for the quarterly period ended September 30, 2003


     [ ]  Transition  report  pursuant  section 13 or 15(d) of the  Securities
          Exchange Act of 1934 for the transition  period from  ____________  to
          ________________

                               eMAGIN CORPORATION
        (Exact name of small business issuer as specified in its charter)

                        Commission file number: 000-24757

       DELAWARE                                                56-1764501
(State or other jurisdiction                   (IRS Employer Identification No.)
 of incorporation or organization)

                                  2070 Route 52
                        Hopewell Junction, New York 12533
                    (Address of principal executive offices)

                                 (845) 892-1900
                           (Issuer's telephone number)
                               -------------------

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes [ X ] No [ ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:
Not applicable

APPLICABLE ONLY TO CORPORATE REGISTRANTS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: As of October 23, 2003 the Registrant
had 41,722,410 shares of Common Stock outstanding.


TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT (check one): Yes [  ]  No [X]

PART I.   FINANCIAL INFORMATION


Index                                                                                                  Page Number

                                                                                                       
Item 1.       Consolidated Financial Statements

              Consolidated Balance Sheets at September 30, 2003 (Unaudited) and                               3
              December 31, 2002 *

              Unaudited Consolidated Statements of Operations for the Three and Nine
              Months ended September 30, 2003 and September 30, 2002                                          4

              Unaudited Consolidated Statements of Cash Flows for the Nine Months ended
              September 30, 2003 and September 30, 2002                                                       5

              Unaudited Consolidated Statement of Changes in Stockholder Equity from
              December 31, 2002 to September 30, 2003                                                         6

              Selected Notes to Consolidated Financial Statements                                             7

              * Information with respect to December 31, 2002 is derived from our audited
                financial statements included on form 10KSB

Item 2.       Management's Discussion and Analysis of Financial Condition and
              Results of Operation                                                                           16

Item 3.       Controls and Procedures                                                                        26

PART II.      OTHER INFORMATION

Item 1.       Legal Proceedings                                                                              26

Item 2.       Changes in Securities and Use of Proceeds                                                      27

Item 3.       Defaults Upon Senior Securities                                                                28

Item 4.       Submission of Matters to a Vote of Security Holders                                            28

Item 5.       Other Information                                                                              29

Item 6.       Exhibits and Reports on Form 8-K                                                               29

SIGNATURE                                                                                                    30


                                    2

                               eMAGIN CORPORATION
                           CONSOLIDATED BALANCE SHEETS


         ------------------------------------------------------------------ -------------------------- ---------------------
                                      ASSETS                                       September 30, 2003   December 31, 2002
         ------------------------------------------------------------------ -------------------------- ---------------------
                                                                                                               
         CURRENT ASSETS:                                                                   (Unaudited)
             Cash and cash equivalents                                                 $    1,378,665         $      82,951
             Trade receivables                                                                785,489               240,136
             Unbilled costs and estimated profits on contracts in progress                     75,359               125,359
             Inventory                                                                        364,257               250,998
             Prepaid expenses and other current assets                                        371,953               113,849
                                                                            -------------------------- ---------------------
               Total current assets                                                         2,975,723               813,293

         EQUIPMENT AND LEASEHOLD IMPROVEMENTS:                                              3,322,094             2,230,674
             Less: Accumulated depreciation                                                (1,966,045)           (1,596,142)
                                                                            -------------------------- ---------------------
               Total equipment and leasehold improvements, net                              1,356,049               634,532

         INTANGIBLE ASSETS:                                                                18,020,000            18,020,000
             Less: Accumulated Amortization                                               (18,020,000)          (17,688,558)
                                                                            -------------------------- ---------------------
               Total intangible assets, net                                                 -   0   -               331,442

         OTHER LONG-TERM ASSETS                                                                98,157                55,117
                                                                            -------------------------- ---------------------
               Total Assets                                                           $     4,429,929         $   1,834,384
                                                                            ========================== =====================

                       LIABILITIES AND SHAREHOLDERS' EQUITY
         CURRENT LIABILITIES:
             Accounts Payable                                                           $     306,803         $   6,381,036
             Accrued payroll and benefits                                                     962,993             1,031,958
             Other accrued expenses                                                            45,042             1,207,693
             Advanced payments                                                                 50,000               -  0  -
             Current portion of long-term debt                                                 48,084                49,275
             Other short-term debt                                                          4,338,319             5,690,889
             Other current liabilities                                                        487,888                53,905
                                                                            -------------------------- ---------------------
               Total current liabilities                                                    6,239,129            14,414,756
                                                                            -------------------------- ---------------------

         NOTES PAYABLE                                                                      1,650,994             -   0   -

         OTHER LONG-TERM DEBT                                                                  39,475               227,742

         SHAREHOLDERS' EQUITY:
             Common Stock, par value $0.0001 per share
             Shares authorized - 200,000,000 and 100,000,000
             Shares issued and outstanding - 41,722,410 and                                    41,722                30,855
             30,854,980
             Additional paid-in-capital                                                   131,030,191           119,221,277
             Deferred compensation                                                           (175,576)             (462,983)
             Accumulated deficit                                                         (134,396,006)         (131,597,263)
                                                                            -------------------------- ---------------------
               Total shareholders' equity                                                  (3,499,669)          (12,808,114)
                                                                            -------------------------- ---------------------

                                                                            -------------------------- ---------------------
               Total liabilities and shareholders' equity                              $    4,429,929         $   1,834,384
                                                                            ========================== =====================

The accompanying notes are an integral part of these consolidated financial statements.

                                       3

                               EMAGIN CORPORATION
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)


                                                          Three months      Three months      Nine months       Nine months
                                                             Ended             Ended            Ended             Ended
                                                          September 30,     September 30,    September 30,     September 30,
                                                             2003              2002              2003             2002
REVENUE:
                                                                                                   
  Contract revenue                                        $   275,504     $        176      $    275,504    $      14,284
  Product revenue, net of returns                             472,983          497,675         1,245,353          909,721
                                                    ------------------ ---------------- ----------------- ----------------
    Total Revenue                                             748,487          497,851         1,520,857          924,005
                                                    ------------------ ---------------- ----------------- ----------------

COSTS OF GOODS SOLD:
  Costs of goods sold                                         393,660                -         1,650,969                -
  Sales commissions                                                                               15,000
                                                    ------------------ ---------------- ----------------- ----------------
    Total Cost of Goods Sold                                  393,660                -         1,665,969                -
                                                    ------------------ ---------------- ----------------- ----------------

Gross Profit (loss)                                           354,827          497,851          (145,112)         924,005

COSTS AND EXPENSES:
  Research and development, net of funding                        571          947,653            22,419        6,435,467
  Manufacturing overhead expense                              945,779                          1,841,145
  Amortization of purchased intangibles                                        331,449           331,442          994,347
  Gain on payable forgiveness                              (2,752,570)                        (4,637,993)
  Stock based compansation                                  1,896,011                -         2,095,407                -
  Selling, general and administrative                         732,438        1,565,377         2,283,476        4,916,824
                                                    ------------------ ---------------- ----------------- ----------------
    Total costs and expenses, net                             822,229        2,844,479         1,935,896       12,346,638
                                                    ------------------ ---------------- ----------------- ----------------

OTHER INCOME (EXPENSE):
  Interest expense                                           (441,749)        (408,010)         (927,255)     (1,822,5652)
  Other Income (expense)                                                                         209,520
                                                    ------------------ ---------------- ----------------- ----------------
  Other income (expense)                                     (441,749)        (408,010)         (717,735)      (1,822,562)
                                                    ------------------ ---------------- ----------------- ----------------

Loss before provision for income taxes                       (909,151)      (2,754,638)       (2,798,743)     (13,245,195)
                                                    ------------------ ---------------- ----------------- ----------------

PROVISION FOR INCOME TAXES
                                                    ------------------ ---------------- ----------------- ----------------
  Net loss                                                $  (909,151)    $ (2,754,638)     $ (2,798,743)   $ (13,245,195)
                                                    ================== ================ ================= ================

Basic and diluted loss per common share                   $     (0.02)    $      (0.09)     $      (0.08)   $       (0.44)

Weighted average common shares outstanding                 38,360,090       30,294,980        34,404,367       30,294,980



 The accompanying notes are an integral part of these consolidated financial statements.


                                       4

                               eMAGIN CORPORATION
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (unaudited)



                                                                                 Nine Months            Nine Months
                                                                                    ended                 ended
                  CASH FLOWS FROM OPERATING ACTIVITIES:                      September 30, 2003     September 30, 2002
                                                                            --------------------- ----------------------
                                                                                                    
Net Loss                                                                            ($2,798,743)          ($14,130,835)
Adjustment to reconcile net loss to net cash used in operating activities:
   Depreciation and amortization                                                        365,535              1,005,413
   Amortization of purchased intangibles                                                331,442                      -
   Amortization of debt discount                                                         69,432                      -
   Non-cash compensation for beneficial conversion                                       32,920                      -
   Non-cash charge for stock based compensation                                       2,095,407              2,627,837
   Non-cash interest related charges                                                    384,368              1,037,335
   Non-cash gain on debt restructure                                                 (4,637,993)                     -
   Non-cash charge for services received                                                443,252                307,657
   Non-cash charge for debt discount                                                     70,979                      -
Changes in operating assets and liabilities:
   Trade receivables                                                                   (545,353)               279,379
   Unbilled costs and estimated profits on contracts in progress                         50,000                191,953
   Inventory                                                                           (113,258)                25,120
   Prepaid expenses and other current assets                                           (312,833)               124,043
   Other long-term assets                                                                61,960                  4,469
   Advanced payment on contracts to be completed                                         59,385               (198,362)
   Deferred revenue                                                                     (29,900)                10,071
   Accounts payable, accrued expenses and accrued payroll                              (560,665)             2,937,190
   Other current liabilities                                                            282,676
                                                                           --------------------- ----------------------
      Net cash used in operating activities                                          (4,751,390)            (5,778,730)
                                                                           --------------------- ----------------------

                  CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases/Sales of equipment                                                           (880,572)               (66,075)
                                                                           --------------------- ----------------------
       Net cash used in investing activities                                           (880,572)               (66,075)
                                                                           --------------------- ----------------------

                  CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sales of common stock, net of issuance costs                                                   3,954,509
Proceeds from exercise of stock options and warrants                                    986,054                    887
Proceeds from long- and short-term debt, net                                          6,000,000              1,443,478
Payments of long-term debt and capital leases                                           (58,378)              (195,284)
                                                                           --------------------- ----------------------
      Net cash provided by financing activities                                       6,927,676              5,203,590
                                                                           --------------------- ----------------------

NET INCREASE IN CASH AND CASH EQUIVALENTS                                             1,295,714               (641,215)
CASH AND CASH EQUIVALENTS, beginning of period                                           82,951                738,342
                                                                           --------------------- ----------------------
 CASH AND CASH EQUIVALENTS, end of period                                           $ 1,378,665            $    97,127
                                                                           ===================== ======================

Non-cash settlements of long-term debt and capital leases                             4,845,537                      -
Reclass of prepaid interest to debt restructure                                         748,116                      -



 The accompanying notes are an integral part of these consolidated financial statements.



                                       5

                               eMAGIN CORPORATION
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

                                   (Unaudited)


                                                                                    Additional
                                         Common Stock                Deferred         Paid-in        Accumulated
                                    Shares             $           Compensation       Capital          Deficit           Total
--------------------------     ---------------- ---------------- ---------------- ---------------- -------------- ------------------
                                                                                                  
Balance, December 31, 2002 ...  $       30,855   $     (462,983)  $   30,854,980   $  119,221,276  $(131,597,263)  $   (12,808,115)
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------

Stock warrants exercised                91,425               91                            49,909                           50,000
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Issuance of common stock for
services .....................         339,433              340                           273,457                          273,796
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Amortization of deferred
compensation .................                                           111,385                                           111,385
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Net loss for period...........                                                                        (2,405,491)       (2,405,491)



Balance, March 31, 2003 ......   $  31,285,838    $      31,286    $    (351,598)   $ 119,544,643  $(134,002,753)   $  (14,778,422)
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------


Conversion to common stock for
debt..........................       4,633,590            4,633                         4,239,260                        4,243,893
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Issuance of common stock for
services......................         125,002              125                            91,970                           92,095
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Exercise of options ..........         129,675              130                            53,810                           53,940
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Issuance of common stock for
payable forgiveness...........       1,997,840            1,998                         1,409,971                        1,411,969
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Amortization of deferred
compensation..................                                            88,011                                            88,011
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Warrants issued with
convertible notes payable.....                                         1,383,203                                         1,383,203
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Beneficial conversion on
financing.....................                                           616,797                                           616,797
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Net income (loss) for period .                                                            515,899                          515,899
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------

Balance, June 30, 2003 .......    $ 38,171,945    $      38,172    $    (263,587)   $ 127,339,654  $(133,486,854)   $  (6,372,615)
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------


Stock warrants exercised .....       1,114,933            1,115                           732,167                         733,282
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Issuance of common stock for
services......................          98,299               98                            77,047                          77,145
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Exercise of options ..........         386,708              387                           148,446                         148,832
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Issuance of common stock for
debt..........................         482,143              482                           716,142                         716,624
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Conversion of debt for common
stock.........................       1,468,382            1,468                           208,735                         210,203
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Amortization of deferred
compensation..................                                                             88,011                          88,011
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Stock Option Compansation.....                                                                         1,808,000        1,808,000
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------
Net income (loss) for period .                                                                          (909,151)        (909,151)
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------

Balance,  September 30, 2003 .      41,722,410    $      41,722    $    (175,576)   $ 131,030,191  $(134,396,006)   $  (3,499,669)
                               ---------------- ---------------- ---------------- ---------------- -------------- ------------------


 The accompanying notes are an integral part of these consolidated financial statements.

                                       6

                               eMAGIN CORPORATION
               Selected Notes to Consolidated Financial Statements


Note 1 - BASIS OF PRESENTATION

The  consolidated  financial  statements  have been prepared in conformity  with
generally  accepted  accounting  principles.  Certain  information  or  footnote
disclosures  normally  included in financial  statements  prepared in accordance
with generally  accepted  accounting  principles  have been condensed or omitted
pursuant to the rules and regulations of the Securities and Exchange Commission.
In the opinion of management,  the statements include all adjustments  necessary
(which are of a normal and recurring  nature) for the fair  presentation  of the
results of the interim  periods  presented.  The results of  operations  for the
period ended September 30, 2003 are not necessarily indicative of the results to
be expected for the full year.

Note 2 - NATURE OF BUSINESS

Fashion Dynamics  Corporation  ("FDC") was organized January 23, 1996, under the
laws of the State of Nevada. FDC had no active business operations other than to
acquire  an  interest  in a  business.  On March  16,  2000,  FDC  acquired  FED
Corporation  ("FED")  (the  "Merger").  The merged  company  changed its name to
eMagin  Corporation  (the "Company" or "eMagin") (Note 3). eMagin is a developer
and manufacturer of optical systems and microdisplays for use in the electronics
industry.  eMagin's wholly-owned  subsidiary,  Virtual Vision Inc., develops and
markets  microdisplay  systems and optics technology for commercial,  industrial
and military  applications.  Following the Merger, the business conducted by the
Company is the business conducted by FED prior to the Merger.

As of January 1, 2003 the  Company  has  completed  its  development  stage,  as
defined  by  Statement  of  Financial   Accounting  Standards  ("SFAS")  No.  7,
Accounting  and  Reporting  by  Development  Stage  Enterprises.  The  financial
statements  results as of December 31, 2002 and the period ended  September  30,
2002 have been  restated to reflect the  current  status.  We expect our product
revenues  to  increase  as we  continue  to  concentrate  on trade  revenue,  as
additional  supplies  arrive  and  volumes of  shipments  of  finished  products
continue to increase.  The effects on accounting  for 2003 will be  substantial.
The majority of sales before 2003 were Contract  Revenue in which our costs were
treated as overall company losses.  In 2002 we started  minimal  production.  We
initially  shipped only developer  kits and sample  quantities of our SVGA+ OLED
microdisplay  product.  We expanded the product line with a SVGA 3D product.  We
now provide both color and several  variations of  monochrome  versions of these
products. Our customers generally spend six to over twelve months evaluating and
testing our product and developing their own end product, which uses our display
before committing to larger orders. We expect the quantities of products shipped
to increase as we receive the materials and supplies we ordered after our recent
financing and we hire additional staff to increase our  manufacturing  capacity,
enabling us to begin shipping  products to fulfill our backlog of orders as well
as ship new orders.

In 2003 we are  keeping  track of costs of  production,  classifying  direct and
indirect  costs to costs of goods sold and tracking our gross  profit.  Although
R&D is no longer our primary focus,  we have a few employees that are working on
projects to create new products and enhance existing products. We are working to
secure new R&D contracts to help create the next generation of lower cost and/or
higher  resolution  products,  as  well  as to  develop  other  performance  and
life-luminance  product  enhancements.  Contract  R&D is expected to continue in
2003, but at proportionately much smaller levels than in prior years.

                                       7

There can be no assurance that the Company will generate  sufficient revenues to
provide  positive  cash flows from  operations.  These and other  factors  raise
substantial  doubt about the Company's  ability to continue as a going  concern.
The  accompanying   consolidated   financial   statements  do  not  include  any
adjustments  that might  result  should the  Company  be unable to  continue  in
existence.

Note 3 - REVENUE AND COST RECOGNITION

The Company has historically  earned revenues from certain of its R&D activities
under both firm fixed-price  contracts and cost-type  contracts,  including some
cost-plus-fee  contracts.  Revenues  relating to firm fixed-price  contracts are
generally  recognized  on the  percentage-of-completion  method of accounting as
costs are incurred  (cost-to-cost  basis).  Revenues on cost-plus-fee  contracts
include costs  incurred plus a portion of estimated fees or profits based on the
relationship of costs incurred to total estimated costs.  Contract costs include
all direct  material and labor costs and an  allocation  of  allowable  indirect
costs as defined by each contract,  as periodically  adjusted to reflect revised
agreed upon rates. These rates are subject to audit by the other party.  Amounts
can be  billed  on a  bi-monthly  basis.  Billing  is based on  subjective  cost
investment  factors.  The  Company is  currently  under  contract to one or more
entities for research and development,  and expects to undertake  activities and
realize  revenues  related  to such  research  and  development  work in  future
quarters.

In addition, the Company has product sales which are recognized when merchandise
is shipped and such  revenue is recorded net of estimated  sales  returns  based
upon past  experience.  Adjustments to such returns are made as new  information
becomes available.

In 2003 we are  keeping  track of costs of  production,  classifying  direct and
indirect costs to cost of goods sold and tracking our gross profit. Although R&D
as our primary  focus will end, we have a few  employees  that are  occasionally
working on projects to create new products  and enhance  existing  products.  At
present,  we have few direct contracts we are billing to, and we may at times be
asked to work on a completed contract. Although we will not have any income from
that work, it may provide a foundation  for future  contracts and we will record
those costs in direct contracts.

Note 4 - RESEARCH AND DEVELOPMENT COSTS

R&D costs are expensed as incurred.  To date, activities of the Company (and its
predecessor) have included the performance of R&D under  cooperative  agreements
with United  States  Government  agencies.  Funding  from such R&D  contracts is
recognized as a reduction in operating  expenses  during the period in which the
services are performed and related direct expenses are incurred.

Note 5 - NET INCOME (LOSS) PER COMMON SHARE

In  accordance  with SFAS No. 128, net income  (loss) per common  share  amounts
("basic  EPS") were  computed  by  dividing  net income  (loss) by the  weighted
average  number  of  common  shares  outstanding  and  excluding  any  potential
dilution.  Net loss per  common  share  assuming  dilution  ("diluted  EPS") was
computed by reflecting  potential  dilution from the exercise of stock  options,
warrants and  convertible  debt where all  contingencies  have been met.  Common
equivalent shares totaling 17,304,028 have been excluded from the computation of
diluted  EPS for the three  months  ended  September  30,  2003,  which  include
5,027,292   weighted   options   in-the-money,   2,169,529   weighted   warrants
in-the-money  and  10,107,207   convertible  shares.  Common  equivalent  shares
totaling  19,091,435  have been excluded from the computation of diluted EPS for
the nine months ended  September  30, 2003,  which  include  5,988,552  weighted
options  in-the-money,  2,995,676 weighted warrants  in-the-money and 10,107,207
convertible  shares.  Common  equivalent  shares  totaling  11,732,954 have been
excluded from the computation of diluted EPS for the three and nine month period
ending September 30, 2002.

                                       8

Note 6 - DEBT

The debt consisted of the following as of September 30, 2003:

         a     Current portion of long term debt             $        48,084
         b     Other short term debt                               4,338,319
         c     Notes payable                                       1,650,994
         d     Other long term debt                                   39,475
         e     Other
                                                        ------------------------
               Total debt                                    $     6,076,872
                                                        ========================

(a) This amount  includes  (i) $11,786 due to Citicorp  Leasing over the next 12
months in lease  payments  for  equipment;  and (ii) $36,298 due to IBM over the
next 12 months for leasehold improvements.

(b) On April 25, 2003, we entered into a global  restructuring  and secured note
purchase  agreement  with  a  group  of  several  accredited  institutional  and
individual  investors  whereby the  Investors  agreed to lend us  $6,000,000  in
exchange  for (i) the  issuance  of  $6,000,000  principal  amount of 9% secured
convertible  promissory  notes  due and  payable  on  November  1, 2005 and (ii)
warrants to purchase an aggregate of 7,749,921  shares of common stock of eMagin
(subject to certain  customary  anti-dilution  adjustments),  such  warrants are
exercisable for a period of three (3) years.

Interest  is payable on the notes at a rate of 9% per annum and,  at our option,
may be paid  through  the  delivery  of shares of our common  stock  (registered
pursuant to the registration rights agreement referred to below) in lieu of cash
interest payments on the maturity date of the loan, November 1, 2005. Subject to
certain limitations, the notes may be converted, at the option of the holder, in
whole or in part,  into common  shares with a  conversion  price of $0.7742,  an
amount equal to 105% of the volume weighted  average of the closing price of our
common  shares as reported  on The  American  Stock  Exchange by the Wall Street
Journal,  New York  City  edition,  for the five (5)  trading  days  immediately
preceding  the closing date.  The exercise  price of the warrants on a per share
basis is $.8110,  an amount equal to 110% of the volume weighted  average of the
closing price of our common shares as reported on The American Stock Exchange by
the Wall Street  Journal,  New York City edition,  for the five (5) trading days
immediately preceding the closing date.

As of September 30, 2003 we received the entire  $6,000,000 of which we received
$2,650,000 in the quarter ended September 30, 2003. As of September 30, 2003 the
Company has  recorded a total of  ($1,268,967)  for original  debt  discount and
($461,663) for beneficial conversion discount. In the third quarter of 2003, the
Company  recorded  ($20,608)  for  the  debt  discount  and  ($48,782)  for  the
beneficial  conversion  as paid in  surplus,  which  will be  amortized  through
November  2005.  The amount  includes  warrants that were exercised in the third
quarter of 2003 and the  reversal of the  remaining  balance of the  unamortized
balance of beneficial  conversion for these exercised warrants.  For the quarter
ended  September  30,  2003,  $38,438 has been  amortized  to  interest  expense
relating to the debt discount for the April 2003 Financing.

The terms of the notes contain certain revisions,  including financial and other
covenants,  which  covenants  relate to  expenses,  direct  cost of goods  sold,
revenues  and  quarterly  revenues.  In the  event  that the  Company  is not in
compliance  with these  covenants,  50% or more of the  holders of the notes (in
terms of the  aggregate  dollar value of the  principal of the notes then issued
and  outstanding  under the note  purchase  agreement)  would be able to call an
event of default.  As of the date of the final  tranche  closing  related to the
April 2003  financing,  we were in violation of one of the  representations  and
warranties  contained in the Note  Purchase  Agreement,  which  violation may be
deemed to constitute a default under the  promissory  notes issued in connection
with  the  April  2003  financing.

                                       9

Such violation relates to the litigation commenced by Vertical Ventures.  We are
in the process of seeking to obtain a forbearance from a majority in interest of
the investors in the April 2003 Financing  pursuant to which they will agree not
to enforce their remedies for such event of default.  We have  reclassified this
debt to short term debt until the forbearance is obtained.

c) This amount  includes:  (i) On January 14, 2002,  the Company  entered into a
$1.0 million bridge loan  arrangement with a private investor in connection with
a secured note purchase  agreement executed by the Company on November 27, 2001.
This  transaction  increased  the total amount of the secured  convertible  loan
outstanding under this arrangement to $1,625,000,  including amounts  previously
made  available to the Company in connection  with the November 27, 2001 secured
note arrangement, net of repayments of $250,000 to certain investors who elected
not to reinvest.  The secured  convertible  notes  accrue  interest at a rate of
9.00% per annum and mature on  November  1, 2005 as a result of a  financing  we
completed  in April  2003.  Terms of the notes  issued on January  14, 2002 also
included a fixed  conversion rate of $0.5264 per share. The Company also granted
warrants  purchasing  921,161  shares of common stock with an exercise  price of
$0.5468 per share to the Investor. Such warrants are exercisable through January
2005. Certain investors (the "Investors") of the November 27, 2001 financing who
elected to remain in the new bridge loan  arrangement  received reset provisions
of the previous  conversion rate and warrant  exercise prices issued in November
2001 equivalent to the terms granted to the investors in January 2002.

The total of the intrinsic  value of the warrants issued to the new Investor and
the  incremental  intrinsic value of the repriced  warrants of certain  existing
investors  of  approximately  $480,000  has  been  recorded  as  original  issue
discount,  resulting  in a reduction  in the  carrying  value of this debt.  The
original issue  discount was amortized  into interest  expense over the original
period of the debt.

In addition,  based on the terms of the bridge loan arrangement,  the conversion
terms of the debt provide for a beneficial  conversion feature.  The total value
of the beneficial feature of the new debt and the incremental value of the reset
conversion  feature of the existing debt of approximately  $780,000 was recorded
at January 14, 2002 as non-cash interest expense.

In  connection  with the April 2003  financing  described  above,  the  Investor
agreed, to (a) amend the secured note issued to them, (b) terminate the security
agreement  dated November 20, 2001 that was entered into in connection  with the
purchase of the original secured notes and allow the new investors to enter into
a new security  agreement with them on a pari passu basis in order for eMagin to
continue its operations as a developer of virtual  imaging  technology,  and (c)
simultaneously  participate  in the new  financing.  The amendments to the notes
included  (i)  extending  the  maturity  dates of the note from June 30, 2003 to
November 1, 2005,  and (ii) revising and  clarifying  certain of the other terms
and  conditions  of the note,  including  provisions  relating  to  default  and
assignment  of the note.  The  defaults  of this note were  modified to the same
conditions as the new financing.

(ii) On June 20, 2002,  the Company  entered  into a $0.2  million  Secured Note
Purchase  Agreement with an Investor.  The secured note accrues  interest at 11%
per annum and was due to mature on  November  1, 2005 as a result of a financing
we completed in April 2003. The Company also granted warrants, exercisable for a
period of five  years,  to  purchase  300,000  shares of  common  stock  with an
exercise  price of $0.4257 per share to the investor;  provided,  however,  this
warrant may not be  exercised  by the  investor  so long as the  investor is the
beneficial owner, directly or indirectly,  of more than ten percent (10%) of the
common stock of eMagin for purposes of Section 16 of the Securities Exchange Act
1934. The fair value of the warrants issued to this Investor, which approximated
$84,000, has been recorded as original issue discount,  resulting in a reduction
in the carrying  value of this debt.  The original  issue discount was amortized
into  interest  expense over the period of the debt.  Pursuant to the April 2003
financing  described above,  the investor agreed,  to (a) amend the secured note
issued to them,  (b) terminate the security  agreement  dated June 20, 2002 that
was entered into in connection  with the purchase of the original  secured notes
and allow the new investors to enter into a new security  agreement with them on
a pari passu basis in order for eMagin to continue its operations as a developer

                                       10

of virtual imaging  technology,  and (c)  simultaneously  participate in the new
financing.  The  amendments to the note included (i) amending the note issued on
June 20, 2002 so as to provide that the note shall be convertible  and will have
the same conversion price as the notes issued pursuant to the April 2003 secured
note purchase agreement, (ii) extending the maturity dates of the note from June
30, 2003 to November 1, 2005, and (iii)  revising and clarifying  certain of the
other  terms  and  conditions  of the note,  including  provisions  relating  to
interest payments,  conversions,  default and assignment of the note. Due to the
amendment to a convertible  note,  we recorded  $106,372  beneficial  conversion
discount and $93,628  original debt discount,  to be amortized  through November
2005.  As of September  30, 2003 the company has  amortized a total of  $12,1699
for original debt discount and $13,825) for beneficial conversion discount. For
the quarter  ended  September  30, 2003, $15,477 has been  amortized to interest
expense.

(d) This amount is due to Citicorp  Leasing as long-term debt for lease payments
for equipment.

(e) Other debt  transactions - On August 21, 2002, the Company issued two Series
B Convertible  Debentures in the amount of $121,739 each.  The  debentures  bore
interest at the rate of 8% per annum and are due August 21, 2004.  The Debenture
also  included  a fixed  conversion  rate of $0.18 per  share.  Article 3 of the
Debentures  provided,  in relevant part,  that the  Debentures  (and any accrued
interest  thereon) may be converted to Common Stock, in whole or in part, on any
Business Day at the Conversion  Price if the average closing price of the shares
traded exceeded a certain price per share for 10 consecutive trading days. These
convertible  debentures  were  converted  on September  10, 2003 into  1,468,382
common shares.  This transaction  included a write-down of $31,561 in beneficial
conversion feature that remained on the books at the time of conversion.

Note 7 - DEBT RESTRUCTURE

In  connection  with the April 2003  Financing,  we entered into  settlement  or
restructuring agreements with certain of our other creditors,  pursuant to which
the  creditors  agreed to accept  shares of our common  stock in full or partial
satisfaction  of the  amount  owed to them,  or which  allow us to  either  make
discounted  payments to them or to make payments  under more  favorable  payment
terms than previously were in place.

We converted  the  $1,000,000  loan plus  interest to Travelers in common shares
totaling  2,137,757  at a  conversion  price  from  the  original  agreement  of
approximately  $0.53 per share, based on the market value of our common stock on
the date the agreement was entered into. In June 2003, we recorded $1,013,017 as
paid in capital for this transaction.  The company also converted the $3,000,000
loan plus interest to SK  Corporation in common shares  totaling  2,495,833 at a
conversion price from the original  agreement of approximately  $1.28 per share,
based on the market  value of our  common  stock on the date the  agreement  was
entered  into.  In June 2003 we recorded $2,883,394  as paid in capital for this
transaction. There was no gain recorded on these transactions

Also in June 2003, the Company negotiated  settlement of amounts due and amounts
for future services  totaling  $418,207 to related parties for services rendered
via issuance of 125,002 shares of common stock.  We also received  approximately
$52,000 for the  exercise of 129,675  option  shares.  We also issued  1,997,840
shares in partial payment of debt in conjunction  with the $1,885,423  reduction
of expense recorded in the financial statement ended June 30, 2003.

In the third  quarter of 2003,  we took  advantage  of several  operating  lease
buyout  provisions.  With a cash outlay of  $950,000,  we  recorded  $950,000 in
purchased  equipment,  a  reduction  of  $598,493  in  prepaid  interest  and  a
write-down of $3,375,000 in long- and short-term debt. We recorded  ($2,752,570)
and  ($4,637,993)  as a gain on  settlement of debt for the three and nine month
ending September 30, 2003, respectively.

                                       11

Note 8 - STOCKHOLDERS' EQUITY

The authorized common stock of the Company consisted of 100,000,000  shares with
a par value of $0.001 per share.  On July 2, 2003 the  shareholders  approved an
increase to 200,000,000 shares.

In September 2003, the Company negotiated  settlement of amounts due and amounts
for future  services to related  parties for  services  rendered via issuance of
98,299 shares of common stock.  As such, the Company  recorded the fair value of
the  services  received  of  $77,145  and  $443,252  in  selling,   general  and
administrative  expenses,  prepaid expenses and reduction of accounts payable in
the  accompanying  audited  consolidated  statement of operations  for the three
months and nine months ending September 30, 2003, respectively.

Also on  September  10, 2003,  the Company  converted  two Series B  Convertible
Debentures in the amount of $121,739 each.  These  convertible  debentures  were
converted at $0.18 per share for a total of 1,468,382  shares.  This transaction
included a write-down of $31,561 in beneficial  conversion feature that remained
on the books at the time of conversion.

Note 9 - STOCK COMPENSATION

As of September 30, 2003,  we have  outstanding  options to purchase  11,920,723
shares.  The Company has elected to follow  Accounting  Principles Board Opinion
No. 25 ("APB No. 25"),  "Accounting  for Stock Issued to Employees," and related
interpretations in accounting for its employee stock options.  Under APB No. 25,
when the exercise price of employee stock options equals the market price of the
underlying stock on the date of grant no compensation  expense is recorded.  The
Company  discloses  information  relating  to  the  fair  value  of  stock-based
compensation  awards  in  accordance  with  Statement  of  Financial  Accounting
Standards  No.123 ("SFAS No. 123"),  "Accounting for Stock-Based  Compensation."
The following table  illustrates the effect on net loss and loss per share as if
the Company had applied the fair value  recognition  provision  of SFAS No. 123.
The fair value of each option  grant is estimated on the date of grant using the
Black-Scholes  option-pricing  model  with the  following  assumptions  used for
grants in the third quarter of 2003 and 2002, respectively: (1) average expected
volatility of 162% and 150%, (2) average  risk-free  interest rates of 3.74% and
6.00%,  and (3)  expected  lives of five and seven  years for the  period  ended
September  30,  2003 and  expected  lives of five and eight years for the period
ended September 30, 2002.

The pro forma amounts that are disclosed in accordance with SFAS No. 123 reflect
the portion of the estimated fair value of awards that were earned for the three
months ended September 30, 2003 and 2002.


  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
                                                                                                            
  For the three and nine months ended                 Three Months         Three Months          Nine Months           Nine Months
  September 30, (In thousands, except per                2003                 2002                  2003                  2002
  share
  amounts)
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Net income (loss) applicable to common                  $(909,151)       $  (2,754,638)        $  (2,798,743)       $ (13,245,195)
  stockholders', as reported:
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Adjust:  Stock-based employee compensation
  expense determined under fair value method                   (316)          (3,116,892)           (1,486,025)          (9,350,676)
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Pro forma net loss                                      $(909,467)       $  (5,871,530)        $  (4,284,768)       $ (22,595,871)

  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Net loss per share applicable to common
  stockholders'
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Basic and diluted, as reported                          $   (0.02)       $       (0.09)        $       (0.08)       $       (0.44)
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------
  Basic and diluted, pro forma                            $   (0.02)       $       (0.19)        $       (0.12)       $       (0.75)
  ---------------------------------------------- --------------------- -------------------- --------------------- ------------------

                                       12

Note 10 - EFFECT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In August 2001, the FASB,  issued SFAS,  No. 143,  "Accounting  for  Obligations
Associated  with the  Retirement of  Long-Lived  Assets." SFAS No. 143 addresses
financial  accounting and reporting for the  retirement  obligation of an asset.
This statement  provides that companies  should  recognize the asset  retirement
cost at its fair value as part of the cost of the asset and classify the accrued
amount as a liability.  The asset  retirement  liability is then accreted to the
ultimate payout as interest  expense.  The initial  measurement of the liability
would be  subsequently  updated for revised  estimates  of the  discounted  cash
outflows.  The Statement will be effective for fiscal years beginning after June
15, 2002. On January 31, 2003, eMagin adopted SFAS No. 143. The adoption of this
standard did not have a significant  impact on eMagin's  consolidated  financial
position, results of operations or cash flows.

In April 2002, the FASB issued SFAS No. 145,  "Rescission of FASB Statements No.
4, 44, and 64,  Amendment of FASB Statement No. 13, and Technical  Corrections."
This statement eliminates the requirement under SFAS 4 to aggregate and classify
all gains and losses from  extinguishment of debt as an extraordinary  item, net
of related income tax effect. This statement also amends SFAS 13 to require that
certain lease  modifications  with economic  effects  similar to  sale-leaseback
transactions be accounted for in the same manner as sale-leaseback transactions.
In addition,  SFAS No. 145 requires  reclassification of gains and losses in all
prior periods  presented in  comparative  financial  statements  related to debt
extinguishment  that  do  not  meet  the  criteria  for  extraordinary  item  in
Accounting  Principles  Board Opinion ("APB") 30. The statement is effective for
fiscal years  beginning after May 15, 2002 with early adoption  encouraged.  The
Company  adopted SFAS No. 145 on January 1, 2003;  the adoption had no effect on
the financial results of the Company.

On July 30, 2002, The FASB issued SFAS No. 146, "Accounting for Costs Associated
with Exit or Disposal  Activities." The standard requires companies to recognize
costs associated with exit or disposal  activities when they are incurred rather
than at the date of a commitment to an exit or disposal plan.  Examples of costs
covered by the standard  include lease  termination  costs and certain  employee
severance  costs  that  are  associated  with  a   restructuring,   discontinued
operation,  plant closing,  or other exit or disposal  activity.  eMagin adopted
SFAS No.  146 as of January 1, 2003.  Upon  adoption  of SFAS 146,  there was no
effect on its financial position, cash flows or results of operations.

In November  2002,  the EITF reached a consensus on Issue 00-21 ("EITF  00-21"),
"Multiple-Deliverable Revenue Arrangements." EITF 00-21 addresses how to account
for  arrangements  that may involve  the  delivery  or  performance  of multiple
products,  services,  and/or rights to use assets. The consensus mandates how to
identify  whether goods or services or both that are to be delivered  separately
in a bundled sales arrangement  should be accounted for separately  because they
are separate units of accounting.  The guidance can affect the timing of revenue
recognition  for  such  arrangements,  even  though  it does  not  change  rules
governing  the  timing or pattern of revenue  recognition  of  individual  items
accounted for  separately.  The final consensus will be applicable to agreements
entered  into in  periods  beginning  after June 15,  2003 with  early  adoption
permitted.  Additionally,  companies  will be permitted  to apply the  consensus
guidance to all existing  arrangements  as the cumulative  effect of a change in
accounting  principle  in  accordance  with  APB  Opinion  No.  20,  "Accounting
Changes."  The  Company is  assessing,  but at this point does not  believe  the
adoption of EIFT 00-21 will have a material  impact on its  financial  position,
cash flows or results of operations.

On April  30,  2003,  the FASB  issued  Statement  No.  149  ("SFAS  No.  149"),
"Amendment of Statement 133 on Derivative  Instruments and Hedging  Activities."
SFAS No.  149  amends  and  clarifies  accounting  for  derivative  instruments,
including certain derivative  instruments  embedded in other contracts,  and for
hedging  activities  under  Statement  No. 133. In  particular,  this  statement
clarifies  under what  circumstances  a contract with an initial net  investment
meets the  characteristic of a derivative as discussed in Statement No. 133, and
it clarifies

                                       13

when a derivative contains a financing component that warrants special reporting
in the statement of cash flows.  SFAS No. 149 is effective for contracts entered
into or modified  after June 30, 2003 and for hedging  relationships  designated
after June 30,  2003 and is to be applied  prospectively.  The  adoption of this
standard did not have a material  impact on the  Company's  financial  position,
cash flows or results of operations.  On May 15, 2003, the FASB issued Statement
No. 150 ("FAS No.  150"),  Accounting  for Certain  Financial  Instruments  with
Characteristics  of  Both  Liabilities  and  Equity.  FAS  No.  150  establishes
standards  for  how  an  issuer   classifies  and  measures  certain   financial
instruments with  characteristics  of both  liabilities and equity.  It requires
that an issuer  classify a  financial  instrument  that is within its scope as a
liability (or an asset in some circumstances).  FAS No. 150 affects the issuer's
accounting for three types of freestanding financial instruments.

     o    mandatorily  redeemable shares, which the issuing company is obligated
          to buy back in exchange for cash or other assets

     o    instruments  that do or may require the issuer to buy back some of its
          shares in exchange for cash or other assets;  includes put options and
          forward purchase contracts

     o    obligations  that can be settled  with shares,  the monetary  value of
          which is fixed,  tied solely or  predominantly to a variable such as a
          market  index,  or varies  inversely  with the  value of the  issuers'
          shares.

FAS No. 150 does not apply to features  embedded in a financial  instrument that
is not a  derivative  in its  entirety.  Most of the  guidance in FAS No. 150 is
effective for all financial  instruments  entered into or modified after May 31,
2003,  and otherwise is effective at the  beginning of the first interim  period
beginning after June 15, 2003. The Company has not yet completed its analysis of
SFAS No. 150 and,  therefore,  the effect on the  Company's  combined  financial
statements of the  implementation of SFAS 150, when effective,  has not yet been
determined.

Note 11 - RECLASSIFICATIONS

Certain  amounts  in the  September  30,  2002  financial  statements  have been
reclassified to conform to the September 2003  classification.  As of January 1,
2003 the Company has completed its development stage, as defined by Statement of
Financial  Accounting  Standards  ("SFAS") No. 7,  Accounting  and  Reporting by
Development Stage Enterprises".  The financial statements results as of December
31, 2002 and the period ended  September  30, 2002 have been restated to reflect
the current status.

Note 12 - CONTINGENCIES

On or about May 19,  2003,  an action  was  commenced  against  the  Company  by
Vertical Ventures Investments LLC in the Supreme Court of the State of New York,
County of New York,  Index No.  3601562/03.  In this action,  the  plaintiff has
asserted  claims for the breach of a Registration  Rights  Agreement,  and seeks
compensatory  damages  against  the  Company  in the amount of  $1,500,000.  The
Company filed its answer on June 23, 2003 and has denied any and all wrongdoing.
The Company  intends to  vigorously  defend this matter.  The parties are in the
process of  conducting  discovery,  but at this  juncture,  it is  difficult  to
estimate the  likelihood of any  unfavorable  outcome and estimate the amount or
range of potential loss at this time.

                                       14

Item 2. Management's  Discussion and Analysis of Financial Condition and Results
        of Operation

Statement of Forward-Looking Information

This report contains  forward-looking  statements  within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934.  These  statements  relate to future  events  or our  future  financial
performance.  In some cases,  you can  identify  forward-looking  statements  by
terminology such as "may," "will,"  "should,"  "expect,"  "plan,"  "anticipate,"
"believe,"  "estimate,"  "predict,"  "potential" or "continue,"  the negative of
such  terms,  or  other  comparable  terminology.   These  statements  are  only
predictions.  Actual events or results may differ  materially  from those in the
forward-looking statements as a result of various important factors. Although we
believe that the expectations  reflected in the  forward-looking  statements are
reasonable,  such should not be regarded as a representation by the Company,  or
any other person,  that such  forward-looking  statements will be achieved.  The
business and operations of the Company are subject to substantial  risks,  which
increase the uncertainty inherent in the forward-looking statements contained in
this release.

We undertake no duty to update any of the forward-looking statements, whether as
a result of new information,  future events or otherwise.  Readers are cautioned
not to place undue reliance on the forward-looking  statements contained in this
report.

Overview

We  design  and  manufacture  miniature  display  modules,  which we refer to as
OLED-on-silicon-microdisplays,  primarily for incorporation into the products of
other  manufacturers.  Microdisplays are typically smaller than a postage stamp,
but when  viewed  through a magnifier  they can  contain all of the  information
appearing on a high-resolution  personal computer screen.  Our microdisplays use
organic light emitting  diodes,  or OLEDs,  which emit light  themselves  when a
current is passed through the device.  Our technology permits OLEDs to be coated
onto silicon chips to produce high resolution OLED-on-silicon microdisplays.

We believe that our  OLED-on-silicon  microdisplays offer a number of advantages
in near to the eye applications  over other current  microdisplay  technologies,
including  lower power  requirements,  less  weight,  fast video  speed  without
flicker,  and  wider  viewing  angles.  In  addition,  many  computer  and video
electronic  system  functions  can be built  directly  into the  OLED-on-silicon
microdisplay,  resulting in compact  systems with lower expected  overall system
costs relative to alternate microdisplay technologies.

Since our inception in 1996, we derived  substantially  all of our revenues from
fees paid to us under  research and  development  contracts,  primarily with the
U.S.  federal  government.   We  have  devoted  significant   resources  to  the
development and commercial launch of our products.  We commenced limited initial
sales of our SVGA+  microdisplay in May 2001 and commenced  shipping  samples of
our SVGA-3D  microdisplay  in February  2002.  As of September  30, 2003, we had
recognized  an  aggregate  of  approximately  $3.4  million  from  sales  of our
products,  and have a backlog of more than $27 million in  products  ordered for
delivery  through  2005.  These  products are being  applied or  considered  for
near-eye and headset  applications in products such as entertainment  and gaming
headsets, handheld Internet and telecommunication  appliances,  viewfinders, and
wearable computers to be manufactured by original  equipment  manufacturer (OEM)
customers.  We have also shipped a limited number of prototypes of our eGlass II
Head-wearable   Display  systems.  In  addition  to  marketing   OLED-on-silicon
microdisplays  as  components,  we also  offer  microdisplays  as an  integrated
package,  which we call Microviewer that includes a compact lens for viewing the
microdisplay and electronic interfaces to convert the signal from our customer's
product  into a viewable  image on the  microdisplay.  Through our wholly  owned
subsidiary,  Virtual Vision, Inc., we are also developing head-wearable displays
that incorporate our Microviewer.

                                       15

We license our core OLED technology from Eastman Kodak and we have developed our
own  technology to create high  performance  OLED-on-silicon  microdisplays  and
related  optical  systems.  We believe our technology  licensing  agreement with
Eastman Kodak, coupled with our own intellectual property portfolio,  gives us a
leadership position in OLED and OLED-on-silicon  microdisplay technology. We are
the only company to demonstrate  publicly and market full-color  OLED-on-silicon
microdisplays.

Company History

Our history has been as a developmental stage company. As of January 1, 2003, we
are no longer a development stage company. We have transitioned to manufacturing
our product and intend to  significantly  increase  our  marketing,  sales,  and
research and development efforts, and expand our operating infrastructure.  Most
of our  operating  expenses  are  fixed in the near  term.  If we are  unable to
generate  significant  revenues,  our net  losses in any given  period  could be
greater than expected.

Critical Accounting Policies

The Securities and Exchange  Commission  ("SEC")  defines  "critical  accounting
policies" as those that require  application  of  management's  most  difficult,
subjective or complex judgments, often as a result of the need to make estimates
about the  effect of matters  that are  inherently  uncertain  and may change in
subsequent periods.

Not  all of the  accounting  policies  require  management  to  make  difficult,
subjective or complex judgments or estimates.  However,  the following  policies
could be deemed to be critical within the SEC definition.

Revenue Recognition

Revenue  on  product  sales  is  recognized  when  persuasive   evidence  of  an
arrangement  exists,  such as when a purchase order or contract is received from
the customer,  the price is fixed, title to the goods has changed and there is a
reasonable  assurance of collection  of the sales  proceeds.  We obtain  written
purchase  authorizations from our customers for a specified amount of product at
a  specified  price  and  consider  delivery  to have  occurred  at the  time of
shipment.  Revenue  is  recognized  at  shipment  and we  record a  reserve  for
estimated  sales  returns,  which is  reflected as a reduction of revenue at the
time of revenue recognition.

Revenues from research and development  activities  relating to firm fixed-price
contracts are generally  recognized  on the  percentage-of-completion  method of
accounting as costs are incurred  (cost-to-cost  basis).  Revenues from research
and development  activities  relating to cost-plus-fee  contracts  include costs
incurred plus a portion of estimated  fees or profits based on the  relationship
of costs incurred to total  estimated  costs.  Contract costs include all direct
material  and labor  costs and an  allocation  of  allowable  indirect  costs as
defined by each contract,  as  periodically  adjusted to reflect  revised agreed
upon rates. These rates are subject to audit by the other party.  Amounts can be
billed on a bi-monthly  basis.  Billing is based on subjective  cost  investment
factors.

Results of Operations

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2003 COMPARED TO THREE AND NINE MONTHS
ENDED SEPTEMBER 30, 2002

Revenues

Revenues  for the three  and nine  months  ended  September  30,  2003 were $0.7
million and $1.5  million,  respectively,  as compared to $0.5  million and $0.9
million for the three and nine months ended  September  30,  2002.  Current year
revenues consisted  primarily of product sales and increased by $0.2 million and
$0.6  million

                                       16

for the three  and nine  months  ended  September  30,  2003,  respectively,  as
compared to the three and nine months ended  September  30,  2003.  We ended the
third quarter with a backlog of over $1.5 million in short term sales orders and
$27  million  longer  term  (within 24  months)  purchase  orders  and  purchase
agreements.  There were $0.3  million and $0.3 million  government  R&D contract
revenues for the three and nine months ended  September 30, 2003,  respectively,
as compared to $200 and  $14,000 for the three and nine months  ended  September
30, 2002.  Government R&D contract revenues will remain  significantly  lower in
2003 as compared  to our  historical  average as the company  focuses on product
revenues  rather than  performing  government  R&D contracts,  although  product
revenues include sales to government  contractors which are funded by government
development or procurement contracts.

Costs and Expenses

Cost of Goods  Sold.  Cost of goods  sold  includes  direct and  indirect  costs
associated  with  production,  inventory loss and outside  commissions.  Cost of
goods  sold for the three and nine  months  ended  September  30,  2003 was $0.4
million and $1.7 million,  respectively.  We were not in full production in 2002
and had no cost of goods sold to compare  against.  Gross profit (loss) was $0.4
million and ($0.1)  million,  respectively,  for the three and nine months ended
September  30,  2003 due  primarily  to line  stoppages  resulting  from lack of
production  materials  as well as  machinery  downtime  in the first and  second
quarter.

Research and  Development.  Research and development  expenses for prior periods
include  salaries,  development  materials,  equipment  leases and  depreciation
expenses,  electronics,  rent, utilities and costs associated with operating our
manufacturing  facility.  In 2003,  research and development  expenses  included
salaries,  development  materials and other costs specifically  allocated to the
development  of new products.  Research and  development  expenses were $600 and
$22,000, respectively, for the three and nine months ended September 30, 2003 as
compared to $1.0  million and $6.4 million  respectively  for the three and nine
months ended  September 30, 2002. Of these  amounts,  we received $0 in 2003, as
compared to $0.3  million and $0.4  million for the three and nine months  ended
September 30, 2002, respectively,  in cost sharing from the U.S. Government. The
$1.0 million and $6.4 million  decrease in gross expenses for the three and nine
months ended  September 30, 2003, as compared to the three and nine months ended
September 30, 2002, reflects reduction in staffing and reduction in expenditures
related to our difficult cash position.

Amortization of Purchased Intangibles.  There was no amortization and write down
of purchased  intangibles  expense for the three months ended September 30, 2003
as compared to $0.3  million for the three  months  ended  September  30,  2002.
Amortization  of  purchased  intangibles  expense  for  the  nine  months  ended
September  30, 2003 was $0.3  million,  as compared to $1.0 million for the nine
months ended September 30, 2002. This is the result of the purchased intangibles
being fully amortized by March 31, 2003.

Gain  on  Payable  Forgiveness.  We have  completed  negotiations  with  various
creditors.  We have been mostly successful in obtaining lower negotiated payment
requirements from our larger creditors.  We have made the negotiated payments on
our debt,  using the funds  from the April  2003  financing.  A credit of ($2.8)
million and ($4.7) million were recorded as a reduction of expense for the three
and nine months ended September 30, 2003, respectively, from these negotiations.
This also has the added benefit of removing  almost all long term lease payments
on our machinery.
                                       17

Stock Based Compansation Non-cash stock-based compensation expense for the three
and  nine  months  ended   September   30,  2003  was  $1.9  and  $2.0  million,
respectively,  as compared to $0.3 million and $1.3 million,  respectively,  for
the three and nine months ended  September  30, 2002.  The non-cash  stock-based
compensation  expense for the three and nine months  ending  September  30, 2003
increased  by $1.6  million and $0.7  million,  respectively.  This  increase is
primarily due to the  difference  between the strike price of the options set at
the market  price when  granted in October  2002 and the price of the  Company's
stock on July 2, 2003 when the options granted in October 2002 were issued under
the 2003 Employee Stock Option Plan. Non-cash stock-based compensation costs are
the result of  amortization  of the intrinsic value ascribed for the issuance of
stock options at the time of grant.  The  amortization  is done over the vesting
period of such options.

Selling,  General  and  Administrative.   Selling,  general  and  administrative
expenses  consist  principally of salaries and fees for  professional  services,
legal fees  incurred  in  connection  with patent  filings and related  matters,
amortization,  as well as other marketing and administrative expenses.  Selling,
general  and  administrative  expenses,  for the  three  and nine  months  ended
September 30, 2003 were $0.7 million and $2.3 million, respectively, as compared
to $1.6 million and $4.9  million for the three and nine months ended  September
30,  2002.  The $0.9  million  and $2.6  million  decrease in the three and nine
months ended September 30, 2003, respectively, as compared to the three and nine
months ended  September  30, 2002,  was  primarily due to the efforts of finding
lower cost suppliers and equity agreements for professional fees, legal fees and
insurance as well as our concentrated efforts to keep our costs lower. We expect
marketing,  general and administrative expenses to increase in future periods as
we  add to  our  sales  staff  and  make  additional  investments  in  marketing
activities.

Other Income  (Expense).  Other income  (expenses) for the three and nine months
ended September 30, 2003 were ($0.4) million and ($0.7)  million,  respectively,
as compared to ($0.4) million and ($1.8)  million,  respectively,  for the three
and nine months  ended  September  30,  2002.  While the three month  comparison
ending September 30, 2003 and 2002 remained unchanged, the nine month comparison
decreased $1.1 million. The decrease in expense for this non-cash charge was due
primarily  to the write down of the  intercompany  balance at 2002 year end.  We
recorded the receipt of $0.2  million  from the sale of old unused  equipment in
the 2nd quarter of 2003.

Liquidity and Capital Resources

Current Financial Position

We have total  liabilities  and  contractual  obligations  of  $11,098,867 as of
September 30, 2003. These contractual obligations, along with the dates on which
such payments are due, are described below:


                                                       Payments Due by Period
                                                       ----------------------
     Contractual Obligations             Total            One Year or Less        More than One Year
     -----------------------        ----------------      ----------------        ------------------
                                                                             
     Due to Related Parties            $        --           $         --             $          --

     Notes Payable - Related
       Parties                                  --                     --                        --

     Convertible Debentures             10,107,207              4,338,319                 5,768,888
     Accounts Payable and
       Accrued Expenses                    991,660                309,364                   682,296
                                    ----------------      ----------------        ------------------
     Total Contractual
       Obligations                     $11,098,867           $  4,647,683             $   6,451,184
                                    ================      ================        ==================

                                       18

In April 2003, we closed on a $6.0 million  financing (see Changes in Securities
and Use of  Proceeds,  Part II Item - 2). We  estimate  that  this $6.0  million
financing is the minimum  amount of funds that we require to support us until we
begin  realizing   profits  from  production  in  sufficient  amount  to  become
profitable  through  production  alone.  No  assurance  can be  given  that  our
estimates will prove to be correct, or that we will generate sufficient revenues
to provide  positive cash flows from  operations.  These and other factors raise
substantial doubt about our ability to continue as a going concern.

During April 2003,  eMagin reached  agreements with certain  creditors and these
agreements were primarily  conditioned  upon actions to be taken and installment
and buyout  payments to be made by eMagin  through  September  30,  2003.  After
making these payments,  eMagin recorded  approximately $3.9 million in reduction
of expenses in the financial statements ended September 30, 2003

We currently  anticipate that we will continue to experience  significant growth
in our  operating  expenses for the  foreseeable  future and that our  operating
expenses will be the principal  use of our cash. In  particular,  we expect that
salaries for employees engaged in production  operations,  purchase of inventory
and expenses of increased  sales and  marketing  efforts  would be the principle
uses of cash. We expect that our cash  requirements over the next 12 months will
be met by a combination  of additional  equity or debt  financing,  and revenues
generated  by sales.  We expect to continue to devote  substantial  resources to
manufacturing, marketing and selling our products.

We have  received  purchase  agreements  for our  products to be  delivered  now
through 2004 and into early 2005.  Management  believes  that the  prospects for
growth of product revenue remain high.

Our customer  schedules  have been  necessarily  pushed out due to our financing
issues,  but these  shipments  are being  renegotiated  now that the  funding is
committed.  We do not currently anticipate any significant loss of business as a
result of our prior financing related product ramp delays,  other than the shift
in  delivery  schedules.  We must ramp our  supplies  and  staffing  quickly and
efficiently to meet the anticipated  shipping schedules.  A significant level of
effort will be required.

We are in the early phases of production, although our progress has been impeded
by our prior cash position. Anticipated increased shipments in the first quarter
were delayed, primarily due to our inability to purchase raw materials. Based on
the planned schedule, we have resolved our supplier issues and have been able to
produce  quantities  in the late  third  quarter  of 2003.  We expect our fourth
quarter revenue to begin to reflect this change.

Our cash requirements  depend on numerous factors,  including  completion of our
product development  activities,  ability to commercialize our products,  timely
market acceptance of our products and our customer's product, and other factors.
We expect to carefully  devote  capital  resources  to continue our  development
programs directed at  commercializing  our products in our target markets,  hire
and train  additional  staff,  expand our research and  development  activities,
develop and expand our manufacturing  capacity and begin production  activities.
Any delays could change the cash  requirements of the company.  While we believe
that we are in position to handle a significant  production increase,  there can
be no assurance  that we will not experience  some issues  relating to yield and
throughput risk that could result in production delays.

Factors Which May Affect Future Results

In  evaluating  our business,  prospective  investors  and  shareholders  should
carefully consider the risks factors, any of which could have a material adverse
impact on our business,  operating results and financial condition and result in
a complete loss of your investment.

                                       19

Risks Related To Our Financial Results

If we cannot  operate as a going  concern,  our stock price will decline and you
may lose your entire investment.  Our auditors included an explanatory paragraph
in their report on our financial statements for the year ended December 31, 2002
which states that, due to recurring  losses from  operations  since inception of
the Company, there is substantial doubt about our ability to continue as a going
concern.  Our financial statements for the three months ended September 30, 2003
do not include any adjustments  that might result from our inability to continue
as a going concern.  These adjustments could include additional  liabilities and
the impairment of certain  assets.  If we had adjusted our financial  statements
for these  uncertainties,  our operating  results and financial  condition would
have been materially and adversely affected.

If we do not obtain additional cash to operate our business,  we may not be able
to execute our  business  plan and may not achieve  profitability.  In the event
that cash flow from  operations  is less than  anticipated  and we are unable to
secure  additional  funding to cover  these added  losses,  in order to preserve
cash, we would be required to further  reduce  expenditures  and effect  further
reductions  in our  corporate  infrastructure,  either  of  which  could  have a
material  adverse  effect  on our  ability  to  continue  our  current  level of
operations. To the extent that operating expenses increase or we need additional
funds to make  acquisitions,  develop  new  technologies  or  acquire  strategic
assets,  the need for additional  funding may be accelerated and there can be no
assurances that any such additional  funding can be obtained on terms acceptable
to us, if at all. If we are not able to generate sufficient capital, either from
operations or through additional financing,  to fund our current operations,  we
may not be able to continue as a going concern.  If we are unable to continue as
a going concern,  we may be forced to significantly  reduce or cease our current
operations.  This could significantly reduce the value of our securities,  which
could  result in our  de-listing  from the  American  Stock  Exchange  and cause
investment losses for our shareholders.

The financing commitments provided in April 2003 substantially improves our
probability of success, but there is no guarantee that any additional expenses
or delays may not adversely effect our cash requirements beyond that provided by
the recent financing. Any significant delay in revenue or increased expense
could result in the default of the secured note agreement, which could result in
a significant or total loss of any unsecured investments in eMagin.

We may not be able to satisfy The American  Stock  Exchange's  (the  "Exchange")
continued listing  requirements.  To maintain the listing of our common stock on
the Exchange,  we are required to meet certain continued  listing  requirements,
including,  but not limited to, the  requirement  that our common stock not sell
for a substantial  period of time at a low price per share, the requirement that
we  maintain a minimum of $2 million  in  shareholder  equity.  In its review of
whether a share price is too low or whether a reverse split is appropriate,  the
Exchange will consider all pertinent  factors,  including  market  conditions in
general, the number of shares outstanding,  plans which may have been formulated
by management,  applicable  regulations of the state of  incorporation or of any
governmental  agency having  jurisdiction  over eMagin,  and the relationship to
other Exchange policies  regarding  continued  listing.  If the Exchange were to
determine  that our share price is too low and that we should  reverse split our
shares but we were  unable to comply  for any  reason,  our common  stock may be
delisted  from the  Exchange.  Delisting  of our common  stock could  materially
adversely  affect the market price, the market liquidity of our common stock and
our  ability  to raise  necessary  capital.  Moreover,  it would  likely be more
difficult to trade in or to obtain accurate quotations as to the market price of
our common  stock.  If the  Exchange  were to  determine  that we were filing to
satisfy the minimum  shareholder  equity  standards,  then we may be required to
establish  a plan to increase  the  shareholder  equity to over $2 million.  The
financing  that we completed in April 2003 was debt based,  and did not directly
increase shareholder equity. However, shareholder equity did improve through the
related conversion of other debt to stock and through negotiated  write-downs of
debt.  Nevertheless,  there will still be a substantial  gap remaining  that may
increase in subsequent  quarters before it begins to improve. If this additional
equity cannot be accomplished  through  operations,  then it may be done through
the sale of equity,  which  could  result in  additional  dilution  to  existing

                                       20

shareholders. The failure to satisfy any Exchange concerns regarding the minimum
equity  standards  could  result in a  delisting  of our  common  stock from the
Exchange.

The AMEX  staff  notified  us in June 2003  that we have  fallen  below  Section
1003(a)(i)  of the AMEX Company  Guide for having  shareholders'  equity of less
than $2,000,000 and losses from continuing  operations  and/or net losses in two
out of the three most recent fiscal years.  We were afforded the  opportunity to
submit a plan of  compliance  to the AMEX and  presented its plan to the AMEX in
July 2003. On September 9, 2003,  we received  notice from the staff of the AMEX
that the AMEX had accepted our plan to regain  compliance with AMEX's  continued
listing  standards and granted us an extension  until December 4, 2004 to regain
compliance with those standards.

We will be subject to  periodic  review by the AMEX staff  during the  extension
period. During this time, we must make progress consistent with the terms of the
plan or maintain  compliance with the continued listing standards.  Other as yet
unidentified  issues may arise that could adversely  affect the financial or the
potential listing status of the company.

We have a history of losses since our  inception  and expect to incur losses for
the foreseeable future. Accumulated losses excluding non-cash transactions as of
September  30,  2003,  were  $32.5  million  and  acquisition  related  non-cash
transactions  were $101.9 million,  which resulted in an accumulated net loss of
$134.4  million,  the majority of which was related to the March 2000 merger and
its subsequent write-down of its goodwill. The non-cash losses were dominated by
the  amortization  and  write-down  of goodwill and  purchased  intangibles  and
write-down of acquired in process research and development  related to the March
2000 acquisition,  and also included some non-cash stock-based compensation.  We
have not yet achieved  profitability  and we can give no assurances that we will
achieve  profitability  within the  foreseeable  future as we fund operating and
capital  expenditures in areas such as  establishment  and expansion of markets,
sales and marketing, operating equipment and research and development. We cannot
assure investors that we will ever achieve or sustain  profitability or that our
operating losses will not increase in the future.  We were previously  primarily
dependent  on U.S.  government  contracts.  The majority of our revenues to date
have been derived from research and development  contracts with the U.S. federal
government. We cannot continue to rely on such contracts for revenue. We plan to
submit proposals for additional development contract funding;  however,  funding
is subject to legislative  authorization and even if funds are appropriated such
funds may be withdrawn based on changes in government priorities.  No assurances
can be given that we will be successful in obtaining new  government  contracts.
Our inability to obtain revenues from government contracts could have a material
adverse  effect on our  results  of  long-term  operations,  unless  substantial
product  or  non-government  contract  revenue  offsets  any lack of  government
contract revenue,  unless substantial product or non-government contract revenue
offsets any lack of government contract revenue.

Risks Related To Our Intellectual Property

We rely on our license  agreement with Eastman Kodak for the  development of our
products, and the termination of this license,  Eastman Kodak's licensing of its
OLED technology to others for microdisplay applications,  or the sublicensing by
Eastman  Kodak of our OLED  technology to third  parties,  could have a material
adverse impact on our business. Our principal products under development utilize
OLED  technology  that we license from Eastman Kodak. We rely upon Eastman Kodak
to protect  and  enforce key  patents  held by Eastman  Kodak,  relating to OLED
display  technology.  Eastman  Kodak's  patents  expire at various  times in the
future. Our license with Eastman Kodak could terminate if we fail to perform any
material term or covenant  under the license  agreement.  Since our license from
Eastman  Kodak is  non-exclusive,  Eastman  Kodak  could  also elect to become a
competitor itself or to license OLED technology for microdisplay applications to
others who have the potential to compete with us. The occurrence of any of these
events could have a material adverse impact on our business.

                                       21

We may not be successful in protecting our intellectual property and proprietary
rights. We rely on a combination of patents, trade secret protection,  licensing
agreements  and other  arrangements  to  establish  and protect our  proprietary
technologies.  If we fail to  successfully  enforce  our  intellectual  property
rights,  our competitive  position could suffer,  which could harm our operating
results.  Patents may not be issued for our current patent  applications,  third
parties  may  challenge,  invalidate  or  circumvent  any  patent  issued to us,
unauthorized  parties  could  obtain  and  use  information  that we  regard  as
proprietary  despite  our  efforts to protect  our  proprietary  rights,  rights
granted under patents issued to us may not afford us any competitive  advantage,
others  may  independently  develop  similar  technology  or design  around  our
patents,  our  technology  may be available to licensees of Eastman  Kodak,  and
protection of our intellectual property rights may be limited in certain foreign
countries.  We may be required to expend  significant  resources  to monitor and
police our intellectual property rights. Any future infringement or other claims
or  prosecutions  related  to our  intellectual  property  could have a material
adverse effect on our business. Any such claims, with or without merit, could be
time  consuming  to defend,  result in costly  litigation,  divert  management's
attention  and  resources,  or  require us to enter  into  royalty or  licensing
agreements.  Such  royalty or  licensing  agreements,  if  required,  may not be
available  on terms  acceptable  to us, if at all.  Protection  of  intellectual
property has  historically  been a large yearly expense for eMagin.  We have not
been  in a  financial  position  to  properly  protect  all of our  intellectual
property,  and may not be in a position to properly protect our position or stay
ahead  of  competition  in new  research  and the  protecting  of the  resulting
intellectual property.

Risks Related To the Microdisplay Industry

The commercial  success of the  microdisplay  industry depends on the widespread
market acceptance of microdisplay systems products. The market for microdisplays
is emerging.  Our success will depend on consumer acceptance of microdisplays as
well as the success of the  commercialization  of the microdisplay market. As an
OEM supplier, our customer's products must also be well accepted. At present, it
is difficult to assess or predict with any assurance the potential size,  timing
and viability of market  opportunities  for our  technology in this market.  The
viewfinder  microdisplay  market  sector  is well  established  with  entrenched
competitors who we must displace.

The microdisplay  systems business is intensely  competitive.  We do business in
intensely  competitive  markets that are  characterized  by rapid  technological
change, changes in market requirements and competition from both other suppliers
and our potential OEM  customers.  Such markets are typically  characterized  by
price erosion. This intense competition could result in pricing pressures, lower
sales,  reduced  margins,  and  lower  market  share.  Our  ability  to  compete
successfully  will  depend on a number of  factors,  both within and outside our
control.  We expect  these  factors to include  the  following:  our  success in
designing,  manufacturing and delivering expected new products,  including those
implementing  new  technologies  on a timely  basis;  our ability to address the
needs of our  customers and the quality of our customer  services;  the quality,
performance,  reliability,  features,  ease of use and pricing of our  products;
successful  expansion  of our  manufacturing  capabilities;  our  efficiency  of
production,  and ability to  manufacture  and ship products on time; the rate at
which  original  equipment   manufacturing  customers  incorporate  our  product
solutions  into their own  products;  the market  acceptance  of our  customers'
products;  and  product or  technology  introductions  by our  competitors.  Our
competitive  position  could be damaged if one or more  potential  OEM customers
decide  to  manufacture  their  own  microdisplays,   using  OLED  or  alternate
technologies.  In  addition,  our  customers  may  be  reluctant  to  rely  on a
relatively  small  company  such as eMagin for a critical  component.  We cannot
assure  you that we will be able to compete  successfully  against  current  and
future  competition,  and the failure to do so would have a  materially  adverse
effect upon our business, operating results and financial condition.

The display  industry is  cyclical.  The display  industry is  characterized  by
fabrication  facilities  that require large capital  expenditures  and long lead
times go construct leading to frequent mismatches between supply and

                                       22

demand. The OLED microdisplay sector may experience overcapacity if and when all
of the  facilities  presently  in the  planning  stage come on line leading to a
difficult market in which to sell our products.

Competing  products  may get to market  sooner than ours.  Our  competitors  are
investing   substantial   resources  in  the   development  and  manufacture  of
microdisplay  systems using  alternative  technologies such as reflective liquid
crystal displays (LCDs),  LCD-on-Silicon ("LCOS")  microdisplays,  active matrix
electroluminescence  and scanning image systems,  and transmissive active matrix
LCDs.

Our  competitors  have  many  advantages  over us.  As the  microdisplay  market
develops, we expect to experience intense competition from numerous domestic and
foreign companies including  well-established  corporations possessing worldwide
manufacturing and production facilities, greater name recognition, larger retail
bases and significantly  greater financial,  technical,  and marketing resources
than us, as well as from emerging companies  attempting to obtain a share of the
various  markets  in which  our  microdisplay  products  have the  potential  to
compete.

Our products  are subject to lengthy OEM  development  periods.  We plan to sell
most of our  microdisplays  to OEMs who will incorporate them into products they
sell. OEMs determine  during their product  development  phase whether they will
incorporate  our  products.  The time elapsed  between  initial  sampling of our
products by OEMs, the custom design of our products to meet specific OEM product
requirements,  and the ultimate  incorporation of our products into OEM consumer
products is significant.  If our products fail to meet our OEM customers'  cost,
performance  or technical  requirements  or if unexpected  technical  challenges
arise in the  integration  of our  products  into  OEM  consumer  products,  our
operating results could be significantly and adversely affected.  Long delays in
achieving  customer  qualification  and  incorporation  of  our  products  could
adversely affect our business.

Our products  will likely  experience  rapidly  declining  unit  prices.  In the
markets in which we expect to compete,  prices of  established  products tend to
decline  significantly  over time. In order to maintain our profit  margins over
the long term,  we believe  that we will need to  continuously  develop  product
enhancements  and new  technologies  that will either slow price declines of our
products or reduce the cost of producing and delivering  our products.  While we
anticipate many opportunities to reduce production costs over time, there can be
no assurance  that these cost reduction  plans will be  successful.  We may also
attempt to offset the  anticipated  decrease  in our  average  selling  price by
introducing new products,  increasing our sales volumes or adjusting our product
mix.  If we fail to do so, our results of  operations  would be  materially  and
adversely affected

Risks Related To Manufacturing

We expect  to  depend on  semiconductor  contract  manufacturers  to supply  our
silicon integrated circuits and other suppliers of key components, materials and
services.  We do not  manufacture  our silicon  integrated  circuits on which we
incorporate  the OLED.  Instead,  we expect to  provide  the  design  layouts to
semiconductor   contract  manufacturers  who  will  manufacture  the  integrated
circuits on silicon  wafers.  We also expect to depend on suppliers of a variety
of other components and services,  including circuit boards,  graphic integrated
circuits,  passive components,  materials and chemicals,  and equipment support.
Our inability to obtain sufficient quantities of high quality silicon integrated
circuits or other necessary components,  materials or services on a timely basis
could result in manufacturing delays,  increased costs and ultimately in reduced
or delayed sales or lost orders which could  materially and adversely affect our
operating results.

The manufacture of  OLED-on-silicon  is new and OLED microdisplays have not been
produced in significant  quantities.  We expect to begin  commercial  production
during  2003 and 2004 to meet  anticipated  demand for our  products.  If we are
unable to produce our  products  in  sufficient  quantity,  we will be unable to
attract  customers.  In  addition,  we cannot  assure you that once we  commence
volume  production we will attain

                                       23

yields at high throughput  that will result in profitable  gross margins or that
we will not  experience  manufacturing  problems which could result in delays in
delivery of orders or product introductions.

We are  dependent  on a  single  manufacturing  line.  We  initially  expect  to
manufacture  our products on a single  manufacturing  line. If we experience any
significant  disruption  in the  operation  of our  manufacturing  facility or a
serious  failure of a critical  piece of  equipment,  we may be unable to supply
microdisplays to our customers. For this reason, some OEMs may also be reluctant
to  commit  a broad  line of  products  to our  microdisplays  without  a second
production facility in place. Interruptions in our manufacturing could be caused
by manufacturing  equipment problems, the introduction of new equipment into the
manufacturing process or delays in the delivery of new manufacturing  equipment.
Lead-time for delivery of manufacturing equipment can be extensive. No assurance
can be  given  that we will  not  lose  potential  sales  or be  unable  to meet
production orders due to production  interruptions in our manufacturing line. In
order to meet the requirements of certain OEMs for multiple manufacturing sites,
we will have to expend capital to secure additional sites and may not be able to
manage multiple sites successfully.

Risks Related To Our Business

Our success depends in a large part on the continuing  service of key personnel.
Changes  in  management  could have an adverse  effect on our  business.  We are
dependent  upon the active  participation  of several key  management  personnel
including  Gary W. Jones,  our Chief  Executive  Officer.  This is especially an
issue  while  the  company  staffing  is small.  We will  also  need to  recruit
additional  management in order to expand  according to our business  plan.  The
failure to attract and retain  additional  management or personnel  could have a
material adverse effect on our operating results and financial performance.

Our success  depends on attracting  and retaining  highly  skilled and qualified
technical  and  consulting  personnel.  We must hire  highly  skilled  technical
personnel as employees and as  independent  contractors  in order to develop our
products.  The competition for skilled technical employees is intense and we may
not be able to retain or recruit such personnel.  We must compete with companies
that possess  greater  financial and other resources than we do, and that may be
more attractive to potential  employees and contractors.  To be competitive,  we
may have to increase the compensation,  bonuses,  stock options and other fringe
benefits offered to employees in order to attract and retain such personnel. The
costs of retaining or attracting  new  personnel  may have a materially  adverse
affect on our business and our operating results.  In addition,  difficulties in
hiring and retaining  technical  personnel could delay the implementation of our
business plan.

Our  business  depends  on new  products  and  technologies.  The market for our
products is characterized by rapid changes in product,  design and manufacturing
process  technologies.  Our success  depends to a large extent on our ability to
develop and  manufacture  new  products  and  technologies  to match the varying
requirements of different customers in order to establish a competitive position
and become profitable.  Furthermore, we must adopt our products and processes to
technological  changes  and  emerging  industry  standards  and  practices  on a
cost-effective  and timely  basis.  Our failure to  accomplish  any of the above
could harm our business and operating results.

We generally do not have long-term contracts with our customers. Our business is
operated on the basis of short-term purchase orders and we cannot guarantee that
we will be able to  obtain  long-term  contracts  for  some  time.  Our  current
purchase  agreements  can be cancelled or revised  without  penalty or a minimal
penalty,  depending on the circumstances.  In the absence of a backlog of orders
that can only be  canceled  with  penalty,  we plan  production  on the basis of
internally generated forecasts of demand, which makes it difficult to accurately
forecast revenues.  If we fail to accurately  forecast  operating  results,  out
business may suffer and the value of your investment in the Company may decline.

                                       24

Our  business  strategy  may  fail  if we  cannot  continue  to  form  strategic
relationships  with  companies  that  manufacture  and use  products  that could
incorporate our OLED-on-silicon  technology. Our prospects will be significantly
affected  by  our  ability  to  develop   strategic   alliances  with  OEMs  for
incorporation of our  OLED-on-silicon  technology into their products.  While we
intend to continue to establish  strategic  relationships  with manufacturers of
electronic  consumer  products,  personal  computers,  chipmakers,  lens makers,
equipment  makers,  material  suppliers and/or systems  assemblers,  there is no
assurance  that we will be able to continue to establish and maintain  strategic
relationships  on  commercially  acceptable  terms,  or that the alliances we do
enter  in to will  realize  their  objectives.  Failure  to do so  would  have a
material adverse effect on our business.

We may need to  obtain  additional  financing,  which  may not be  available  on
suitable  terms,  and as a  result  our  ability  to grow or  continue  existing
operations may be limited.  Our future  liquidity and capital  requirements  are
difficult to predict  because  they depend on numerous  factors,  including  our
success  in  completing  the  development  of our  products,  manufacturing  and
marketing our products and competing  technological and market developments.  We
may not be  able  to  generate  sufficient  cash  from  our  operations  to meet
additional working capital requirements, support additional capital expenditures
or  take  advantage  of  acquisition  opportunities.  In  addition,  substantial
additional capital may be required in the future to fund product development and
product launches.  No assurance can be given that such additional financing will
be available or that, if available,  such  financing will be obtainable on terms
favorable to our shareholders or us. To the extent we raise  additional  capital
by  issuing  equity  or  securities   convertible   into  equity,   our  current
shareholders   will  suffer   dilution  in  ownership.   If  needed  capital  is
unavailable,  our ability to continue to operate and grow our business  could be
adversely  affected.  Even if capital is available at acceptable  cost, we might
not be able to manage growth effectively.

Our business depends to some extent on international  transactions.  We purchase
needed materials from companies located abroad and may be adversely  affected by
political and currency risk, as well as the  additional  costs of doing business
with a foreign entity.  Some customers in other countries have longer receivable
periods or warranty  periods.  In  addition,  many of the OEMs that are the most
likely long-term  purchasers of our microdisplays are located abroad exposing us
to additional  political  and currency  risk. We may find it necessary to locate
manufacturing  facilities  abroad to be closer to our customers which could give
expose  us  to  various  risks   including   management   of  a   multi-national
organization,  the  complexities  of  complying  with  foreign  law and  custom,
political   instability   and  the   complexities   of   taxation   in  multiple
jurisdictions.

Our business may expose us to product liability claims.  Our business exposes us
to potential product  liability claims.  Although no such claim has been brought
against us to date,  and to our knowledge no such claim is threatened or likely,
we may face  liability to product  users for damages  resulting  from the faulty
design  or  manufacture  of our  products.  While  we plan to  maintain  product
liability insurance  coverage,  there can be no assurance that product liability
claims will not exceed coverage limits, fall outside the scope of such coverage,
or that such insurance will continue to be available at commercially  reasonable
rates, if at all.

Our business is subject to  environmental  regulations  and  possible  liability
arising from potential employee claims of exposure to harmful substances used in
the  development  and  manufacture  of our  products.  We are subject to various
governmental  regulations  related to toxic,  volatile,  experimental  and other
hazardous chemicals used in our design and manufacturing process. Our failure to
comply with these  regulations could result in the imposition of fines or in the
suspension or cessation of our  operations.  Compliance  with these  regulations
could  require us to acquire  costly  equipment  or to incur  other  significant
expenses.  We  develop,  evaluate  and  utilize new  chemical  compounds  in the
manufacture  of our products.  While we attempt to ensure that our employees are
protected  from  exposure  to  hazardous  materials  we cannot  assure  you that
potentially  harmful  exposure  will not  occur or that we will not be liable to
employees as a result.

                                       25

Risks Related To Our Stock

The  substantial  number of shares that are or will be  eligible  for sale could
cause our common stock price to decline even if the Company is successful. Sales
of significant  amounts of common stock in the public market,  or the perception
that such  sales may occur,  could  materially  affect  the market  price of our
common  stock.  These  sales  might also make it more  difficult  for us to sell
equity or  equity-related  securities  in the future at a time and price that we
deem  appropriate.  As of September  30, 2003,  we have  outstanding  options to
purchase  11,892,186  shares.  There are also  outstanding  warrants to purchase
12,986,221  shares of  common  stock.  Conversion  of the  secured  notes is not
certain, even if the share price increases substantially. If the secured were to
convert, they would result in additional outstanding common shares.

We have a staggered Board of Directors and other anti-takeover provisions, which
could inhibit  potential  investors or delay or prevent a change of control that
may favor you.  Our Board of  Directors  is divided  into three  classes and our
Board members are elected for terms that are  staggered.  This could  discourage
the efforts by others to obtain  control of the company.  Some of the provisions
of our certificate of incorporation, our bylaws and Delaware law could, together
or separately,  discourage potential acquisition proposals or delay or prevent a
change in control. In particular,  our board of directors is authorized to issue
up to  10,000,000  shares of  preferred  stock (less any  outstanding  shares of
preferred  stock) with rights and privileges  that might be senior to our common
stock, without the consent of the holders of the common stock.

ITEM 3.  Controls and Procedures

An evaluation was performed under the supervision and with the  participation of
our management,  including the chief executive officer,  or CEO, who is also the
acting chief financial  officer,  or CFO, of the effectiveness of the design and
operation  of  our  disclosure  procedures.   Based  on  that  evaluation,   our
management,  including the CEO and CFO,  concluded that our disclosure  controls
and  procedures  were  effective  as of September  30, 2003.  There have been no
significant  changes in our  internal  control over  financial  reporting in the
third quarter of 2003 that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.


PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any material legal proceedings, except as described below.

On or about April 21, 2003,  eMagin and IBM entered into a Stipulation  in order
to settle an eviction proceeding  originally  commenced by IBM against eMagin on
or about April 9, 2003. Thereafter, in accordance with the Stipulation, on April
23, 2003 the  Stipulation  was presented  to, and approved by, the court,  and a
Judgment was issued in favor of IBM.  Pursuant to the Judgment and  Stipulation,
(i)  eMagin  paid IBM all rent due and  owing to IBM,  and (ii) IBM was  awarded
possession  of the leased  premises,  was issued a warrant to remove eMagin from
possession  of the leased  premises,  and obtained a monetary  judgment for rent
arrears  in the sum of Eight  Hundred  Thirteen  Thousand  Fifty Five and 65/100
($813,055.65)  Dollars,  which sum is to be paid in equal  monthly  installments
during the period commencing May 1, 2003 and ending on March 1, 2004.

                                       26

Such  Judgment  is being  held in escrow by IBM's  attorney  and the  warrant of
eviction is being  stayed,  so long as the Company  continues to timely pay make
the  installment  payments  during  the next 12 months and any  additional  rent
and/or other sums due under the Lease.

On or about May 19,  2003,  an action  was  commenced  against  the  Company  by
Vertical Ventures Investments LLC in the Supreme Court of the State of New York,
County of New York,  Index  No.3601562/03.  In this action,  the  plaintiff  has
asserted  claims for the breach of a Registration  Rights  Agreement,  and seeks
compensatory  damages  against  the  Company  in the amount of  $1,500,000.  The
Company filed its answer on June 23, 2003 and has denied any and all wrongdoing.
The Company  intends to  vigorously  defend this matter.  The parties are in the
process of  conducting  discovery,  but at this  juncture,  it is  difficult  to
estimate the  likelihood of any  unfavorable  outcome and estimate the amount or
range of potential loss at this time.

Item 2. Changes in Securities and Use of Proceeds

On April 25,  2003,  we entered  into a global  restructuring  and secured  note
purchase  agreement  with  a  group  of  several  accredited  institutional  and
individual  investors  whereby the  Investors  agreed to lend us  $6,000,000  in
exchange  for (i) the  issuance  of  $6,000,000  principal  amount of 9% secured
convertible  promissory  notes  due on  November  1, 2005 and (ii)  warrants  to
purchase an aggregate of 7,749,921  shares of common stock of eMagin (subject to
certain customary anti-dilution adjustments), which Warrants are exercisable for
a period of three (3) years.

Interest  is payable on the notes at a rate of 9% per annum and,  at our option,
may be paid  through  the  delivery  of shares of our common  stock  (registered
pursuant to the registration rights agreement referred to below) in lieu of cash
interest payments.  Subject to certain limitations,  the notes may be converted,
at the option of the  holder,  in whole or in part,  into  common  shares with a
conversion price equal to $0.7742 per share, 105% of the volume weighted average
of the closing  price of our common  shares as reported  on The  American  Stock
Exchange by the Wall Street  Journal,  New York City  edition,  for the five (5)
trading  days  immediately  preceding  the closing  date (April 25,  2003).  The
exercise  price of the warrants on a per share basis is $.8110,  an amount equal
to 110% of the volume weighted average of the closing price of our common shares
as reported on The American Stock Exchange by the Wall Street Journal,  New York
City edition,  for the five (5) trading days  immediately  preceding the closing
date (April 25, 2003).

As part of the  transactions,  the  existing  the  holders  of an  aggregate  of
$1,625,000  principal amount of secured notes that were purchased  pursuant to a
secured note purchase  agreement  entered into as of November 27, 2001,  and the
holder of a $200,000  principal amount secured note that was purchased  pursuant
to a secured note purchase agreement entered into as of June 20, 2002, agreed to
(a) amend their  respective  notes issued to them,  (b) terminate the respective
security  agreements dated November 20, 2001 and June 20, 2002 that were entered
into in connection  with the purchase of their notes and allow the new investors
to enter into a new security  agreement with them on a pari passu basis in order
for  eMagin to  continue  its  operations  as a  developer  of  virtual  imaging
technology,  and (c)  simultaneously  participate in this new round of financing
(subject to the terms and  conditions  set forth in the April 2003  secured note
purchase agreement).  The amendments to the notes included (i) amending the note
issued on June 20, 2002 so as to provide that the note shall be convertible  and
will have the same  conversion  price as the notes issued  pursuant to the April
2003 secured note purchase  agreement,  (ii) extending the maturity dates of the
notes from June 30, 2003 to November 1, 2005,  and (iii) revising and clarifying
certain of the other terms and  conditions  of the notes,  including  provisions
relating to interest  payments,  conversions,  default  and  assignments  of the
notes.

In  connection  with the  completion  of the  transactions  under the April 2003
securities  purchase  agreement,  we also entered into a security agreement with
the Investors  dated as of April 25, 2003, and a registration  rights  agreement
dated as of April 25, 2003  providing  the investors  with certain  registration
rights under the Securities

                                       27

Act of 1933, as amended,  with respect to our common stock issued or issuable in
lieu of cash interest payments on the notes, upon conversion of the notes and/or
exercise of the warrants.

In addition to the  foregoing,  as a condition  to and  simultaneously  with the
closing of the  transaction  pursuant to the secured  note  purchase  agreement,
certain holders of our convertible  notes agreed to convert  approximately  $4.9
million of notes and accrued  interest into shares of our common stock,  subject
to  a  "lock  up"  arrangement  allowing  only  limited  sales  through  private
transactions for their remaining shares through December 31, 2003. Specifically,
The Travelers  Insurance Company agreed to convert their $1 million  convertible
note plus  related  interest  into our  common  stock at a  conversion  price of
approximately  $0.53 per share,  and SK Corporation has agreed to convert its $3
million  convertible  note and  accrued  interest  into our  common  stock at an
approximate  conversion  price of  approximately  $1.28 per  share.  As  further
conditions  to the  closing of the  transaction  pursuant  to the  secured  note
purchase  agreement,  we have also  entered  into  settlement  or  restructuring
agreements  with certain of our other  creditors  to whom we owed  approximately
$5.2 million of current payables, pursuant to which the creditors have agreed to
accept shares of our common stock in full or partial  satisfaction of the amount
owed to them, or which allow us to either make discounted payments to them or to
make payments under more favorable payment terms than previously were in place.

On  September  10,  2003  we  converted  Farmers  and   Mid-Century's   $243,478
convertible  notes and accrued  interest  into our common  stock at a conversion
price of $0.18 per share.  This share price was  determined  from Section  2(i),
Automatic Conversion of Note Purchase Agreement, in our Note Purchase Agreement.

The  issuance  of the  shares and the  warrants  was  exempt  from  registration
requirements  of the  Securities  Act of 1933  pursuant to Section  4(2) of such
Securities  Act  and  Regulation  D  promulgated   thereunder   based  upon  the
representations  of each of the Investors that it was an  "accredited  investor"
(as defined  under Rule 501 of  Regulation  D) and that it was  purchasing  such
securities  without a present view toward a distribution of the  securities.  In
addition,  there was no general  advertisement  conducted in connection with the
sale of the securities.


Item 3. Defaults Upon Senior Securities

As of the date of the final tranche closing related to the April 2003 financing,
we were in violation of one of the representations  and warranties  contained in
the Note  Purchase  Agreement,  which  violation  may be deemed to  constitute a
default  under the  promissory  notes issued in  connection  with the April 2003
financing.  Such  violation  relates to the  litigation  commenced  by  Vertical
Ventures.  We are in the  process  of  seeking  to obtain a  forbearance  from a
majority in interest of the  investors in the April 2003  Financing  pursuant to
which they will agree not to enforce their remedies for such event of default.


Item 4. Submission of Matters to a Vote of Security Holders

1.   The Annual Meeting was held at the American Stock Exchange in New York City
     on July 2, 2003 at 11:00 AM.

2.   There were present in person or by proxy 23,730,586 shares of Common Stock,
     of a total of 37,859,063 shares of Common Stock entitled to vote.

3.   The  number  of  shares  voted in favor of the  election  of the  following
     nominees for director is set forth opposite each nominee's name:

                                       28

                  Nominee                            No. of Shares
                  -------                            -------------
                  Gary W. Jones                        22,662,187
                  Jack Rivkin                          21,554,613
                  Paul C. Cronson                      22,129,946

4.   21,114,317  shares were voted in favor of the  amendment  of the  Company's
     Certificate of Incorporation to increase the authorized number of shares of
     common stock from 100,000,000 shares to 200,000,000 shares.

5.   20,998,068  shares were voted in favor to authorize  the board of directors
     to effect a 1 for 10 reverse stock split,  upon  determination by the board
     that such reverse stock split in the best interest of the Company.

6.   20,787,324 shares were voted in favor of 2003 Stock Option Plan.

7.   22,569,716  shares were voted in favor of the appointment of Grant Thornton
     as auditors for 2002 and 2003.


Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

(a)        Exhibits:

EXHIBIT
NUMBER                         DESCRIPTION

31.1 Certification by Chief Executive Officer and Acting Chief Financial Officer
     pursuant to Sarbanes -Oxley Section 302.

32.1 Certification by Chief Executive Officer and Acting Chief Financial Officer
     and pursuant to 18 U.S. C. Section 1350

(b)      Reports on Form 8-K

The Company filed one report on form 8-K during the quarter ended September 30,
2003. Information regarding the items reported on is as follows:

DATE OF REPORT                      ITEM REPORTED ON


July 3, 2003       The Company announced the results of the 2003 Annual Meeting.

                   The Board of Directors approved two
                   amendments to the Companies 2003 Stock
                   Option Plan; (i) reduce the number of
                   shares that may be provided under the
                   "evergreen" provisions and (ii) require
                   shareholder approval for any subsequent
                   increase.

                                       29

                                   SIGNATURES

     In accordance with the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                                              eMAGIN CORPORATION


Dated:  November 13, 2003                     By:/S/ Gary W. Jones
                                                 -----------------
                                                 Gary W. Jones
                                                 Chief Executive Officer and
                                                 Acting Chief Financial Officer
                                       30